E. Danielson
New England Journal of Medicine · 2001–2009
A researcher in the Science corpus: 5 papers; trusts 0 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Whom E. Danielson trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts E. Danielson overall
Papers from E. Danielson's perspective
Ordered by how strongly the researchers E. Danielson trusts endorse each paper. Same corpus, a different order for every researcher.
- High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. (Circulation)
- Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial… (Journal of the American Medical Association (JAMA))
- Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein (Circulation)
- Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (Journal of the American Pharmacists Association)
- Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study (Circulation)
- Intravascular ultrasound: novel pathophysiological insights and current clinical applications. (Circulation)
- Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells (Circulation)
- Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. (Arteriosclerosis, Thrombosis and Vascular Biology)
- The thin-cap fibroatheroma: a type of vulnerable plaque: The major precursor lesion to acute coronary syndromes (Current Opinion in Cardiology)
- Task Force on Sudden Cardiac Death of the European Society of Cardiology. (European Heart Journal)
Their papers
- Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. (2009) — 1,030 citations
- A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism: the JUPITER Trial (2009) — 730 citations
- Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. (2008) — 6,106 citations
- Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (2003) — 777 citations
- Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. (2001) — 1,611 citations